Watson Pharmaceuticals, Inc. has announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women’s Health, Inc. on outstanding patent litigation related to Teva’s Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson’s Quasense® product, which is a generic equivalent of Teva’s Seasonale®. Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg). Watson further admits that the licensed patents are valid and enforceable.